Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
05 Oktober 2023 - 1:30PM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced that
third quarter of fiscal year 2023 financial results will be
reported after the market closes on Thursday, November 9th.
Management will host a conference call at 5:00
p.m. Eastern Time on November 9th to discuss the results of the
quarter and provide a corporate update with a question and answer
session. Those who would like to participate may access the live
webcast here, or access the teleconference here. The live webcast
can also be accessed via the company’s website at
investors.organogenesis.com. The webcast will be archived on the
company website for approximately one year.
About Organogenesis Holdings
Inc. Organogenesis Holdings Inc. is a leading regenerative
medicine company focused on the development, manufacture and
commercialization of solutions for the advanced wound care and
surgical and sports medicine markets. Organogenesis offers a
comprehensive portfolio of innovative regenerative products to
address patient needs across the continuum of care. For more
information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
Ron O’Brien
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
Von Sep 2023 bis Sep 2024